- State-owned pharmaceutical company Bio Farma did not elaborate whether the interim result was from a late-stage clinical trial
- Over one million doses of the experimental Covid-19 shot developed by the Chinese firm arrived in Indonesia last week
Reuters
Published: 6:13pm, 8 Dec,
Indonesia’s state-owned pharmaceutical company Bio Farma said on Tuesday that interim data on trials it was conducting on Covid-19 vaccines produced by the Chinese company Sinovac showed up to 97 per cent efficacy.
“Our clinical trial team found, within one month, that the interim data shows up to 97 per cent for its efficacy,” said Iwan Setiawan, a spokesman for Bio Farma, at a news conference.
He did not elaborate whether the interim result was from a late-stage clinical trial, but another Bio Farma spokesman said that the company is still gathering data on efficacy from ongoing Phase 3 trial.
Sinovac had said earlier that 97 per cent of healthy adults receiving lower dosage taking part in its Phase 1-2 trial showed antibody-related immune response after taking its Covid-19 vaccine CoronaVac.
